title: Bioinnovation Enterprise: An engine driving breakthrough therapies.
abstract: Biological advances have radically expanded our insights into the underpinnings of health and disease. New knowledge has formed the substrate for translation-expedited in turn by the biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the management of patients and populations. Indeed, this Bioinnovation Enterprise has become the dominant growth sector in drug development and the engine driving the translation of breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights in pathobiology into transformative therapies.
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Waldman
authors.affiliation: Mayo Clinic Center for Regenerative Medicine, Divisions of Cardiovascular Diseases and Clinical Pharmacology, Departments of Medicine, Molecular Pharmacology and Experimental Therapeutics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: A
authors.initials: A
authors.lastname: Terzic
mesh_terms: D001709:Biotechnology; D006801:Humans; D035703:Therapies, Investigational; D057170:Translational Research, Biomedical